Iranian Polymer Journal

, Volume 27, Issue 4, pp 263–274 | Cite as

Novel NGR anchored pullulan micelles for controlled and targeted delivery of doxorubicin to HeLa cancerous cells

  • Farshid Hassanzadeh
  • Elahe Mahmoudi
  • Jaleh Varshosaz
  • Ghadam Ali Khodarahmi
  • Mahboubeh Rostami
  • Mostafa Ghanadian
  • Nasim Dana
Original Research
  • 26 Downloads

Abstract

Doxorubicin (DOX) is used to treat different kinds of cancers, including cervix carcinoma. However, it has various side effects such as cardiotoxicity. Nano-sized controlled releasing carriers such as polymeric micelles are of interesting approaches to overcome these side effects of doxorubicin in cancer chemotherapy. Regarding the up-regulation of CD13/APN receptors on the cervix carcinoma cells, which can bind to peptide sequences specially NGR (asparagine–glycine–arginine) with high affinity, peptide sequence (NGR) targeted micelles would lead to effective treatment of this carcinoma. In this study, the NGR peptide sequence was synthesized using the solution-phase strategy from asparagine, glycine, and arginine residues. The pullulan–retinoic acid conjugate and pullulan–retinoic acid–NGR conjugate were prepared by the amide and ester bond formation between the hydroxyl groups of pullulan and carboxylic acid groups of retinoic acid and peptide sequence. Pullulan–retinoic acid–NGR micelles were prepared by the direct dissolution method. The optimized micelles, according to their particle size (124.5 nm), zeta potential (− 3.65 mV), entrapment efficiency (85%), and release of DOX (70%, within 72 h) were assessed for their cytotoxicity on HeLa cells using MTT assay. NGR-targeted pullulan/retinoic acid micelles had higher cytotoxicity than the free DOX in cell culture studies on the HeLa cell line, and this can be a promising result in the treatment of cervix carcinoma.

Keywords

Aminopeptidase N NGR Pullulan Polymeric micelle Doxorubicin (DOX) Cervix cancer 

Notes

Acknowledgements

We acknowledge the financial support of Novel Drug Delivery Systems Research Center at Isfahan University of Medical Sciences, Grant Number: 293317.

Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interests.

References

  1. 1.
    Wang X, Wang B, Zhang Q (2011) Anti-tumor targeted drug delivery systems mediated by aminopeptidase N/CD13. Acta Pharm Sin B1:80–83CrossRefGoogle Scholar
  2. 2.
    Wickström M, Larsson R, Nygren P, Gullbo J (2011) Aminopeptidase N (CD13) as a target for cancer chemotherapy. Cancer Sci 102:501–508CrossRefGoogle Scholar
  3. 3.
    Corti A, Fiocchi M, Curnis F (2017) Targeting CD13 with Asn–Gly–Arg (NGR) peptide-drug conjugates. In: Next-generation therapies and technologies for immune-mediated inflammatory diseases (Chap 6). Springer, Berlin, pp 101–122Google Scholar
  4. 4.
    Dixon J, Kaklamanis L, Turley H, Hickson I, Leek R, Harris A, Gatter K (1994) Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 47:43–47CrossRefGoogle Scholar
  5. 5.
    van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HM, Pinedo HM, Hoekman K (2002) Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res 8:3747–3754Google Scholar
  6. 6.
    Atherton AJ, Monaghan P, Warburton MJ, Gusterson BA (1992) Immunocytochemical localization of the ectoenzyme aminopeptidase N in the human breast. J Histochem Cytochem 40:705–710CrossRefGoogle Scholar
  7. 7.
    Fujimura H, Ino K, Nagasaka T, Nakashima N, Nakazato H, Kikkawa F, Mizutani S (2000) Aminopeptidase A expression in cervical neoplasia and its relationship to neoplastic transformation and progression. Oncology 58:342–352CrossRefGoogle Scholar
  8. 8.
    Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60:722–727Google Scholar
  9. 9.
    Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20:122–128CrossRefGoogle Scholar
  10. 10.
    Boohaker RJ, Lee MW, Vishnubhotla P, Perez JLM, Khaled AR (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794–3804CrossRefGoogle Scholar
  11. 11.
    Xiao YF, Jie MM, Li BS, Hu CJ, Xie R, Tang B, Yang SM (2015) Peptide-based treatment: a promising cancer therapy. J Immunol Res 2015(6):1–13.  https://doi.org/10.1155/2015/761820 CrossRefGoogle Scholar
  12. 12.
    Simnick AJ, Amiram M, Liu W, Hanna G, Dewhirst MW, Kontos CD, Chilkoti A (2011) In vivo tumor targeting by a NGR-decorated micelle of a recombinant diblock copolypeptide. J Control Release 155:144–151CrossRefGoogle Scholar
  13. 13.
    Chen Y, Wu JJ, Huang L (2010) Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18:828–834CrossRefGoogle Scholar
  14. 14.
    Ding F, Wu F, Tian Q, Guo L, Wang J, Xiao F, Yu Y (2016) A tumor-targeting drug delivery system based on cyclic NGR-modified, combretastatin A4-loaded, functionalized graphene oxide nanosheets. RSC Adv 6:68134–68140CrossRefGoogle Scholar
  15. 15.
    Kermanizadeh A, Villadsen K, Østrem RG, Jensen KJ, Møller P, Loft S (2017) Integrin targeting and toxicological assessment of peptide-conjugated liposome delivery systems to activated endothelial cells. Basic Clin Pharmacol Toxicol 120:380–389CrossRefGoogle Scholar
  16. 16.
    Negussie AH, Miller JL, Reddy G, Drake SK, Wood BJ, Dreher MR (2010) Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release 143:265–273CrossRefGoogle Scholar
  17. 17.
    Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380CrossRefGoogle Scholar
  18. 18.
    Lin W, Xie X, Deng J, Liu H, Chen Y, Fu X, Liu H, Yang Y (2016) Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery. ‎J Drug Target 24:134–146CrossRefGoogle Scholar
  19. 19.
    Sun Y, Kang C, Yao Z, Liu F, Zhou Y (2016) Peptide-based ligand for active delivery of liposomal doxorubicin. Nano Life 6:1642004CrossRefGoogle Scholar
  20. 20.
    Chandrudu S, Simerska P, Toth I (2013) Chemical methods for peptide and protein production. Molecules 18:4373–4388CrossRefGoogle Scholar
  21. 21.
    Nishiuchi Y, Inui T, Nishio H, Bódi J, Kimura T, Tsuji FI, Sakakibara S (1998) Chemical synthesis of the precursor molecule of the Aequorea green fluorescent protein, subsequent folding, and development of fluorescence. Proc Natl Acad Sci 95:13549–13554CrossRefGoogle Scholar
  22. 22.
    Vigneaud Vd, Ressler C, Swan CJM, Roberts CW, Katsoyannis PG, Gordon S (1953) The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc 75:4879–4880CrossRefGoogle Scholar
  23. 23.
    Ahmad Z, Shah A, Siddiq M, Kraatz H-B (2014) Polymeric micelles as drug delivery vehicles. RSC Adv 4:17028–17038CrossRefGoogle Scholar
  24. 24.
    Yokoyama M (2014) Polymeric micelles as drug carriers: their lights and shadows. J Drug Target 22:576–583CrossRefGoogle Scholar
  25. 25.
    Zhang Y, Huang Y, Li S (2014) Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech 15:862–871CrossRefGoogle Scholar
  26. 26.
    Cheng K-C, Demirci A, Catchmark JM (2011) Pullulan: biosynthesis, production, and applications. Appl Microbiol Biotechnol 92:29.  https://doi.org/10.1007/s00253-011-3477-y CrossRefGoogle Scholar
  27. 27.
    Akiyoshi K, Kobayashi S, Shichibe S, Mix D, Baudys M, Kim SW, Sunamoto J (1998) Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Release 54:313–320CrossRefGoogle Scholar
  28. 28.
    Seo S, Lee CS, Jung YS, Na K (2012) Thermo-sensitivity and triggered drug release of polysaccharide nanogels derived from pullulan-g-poly(l-lactide) copolymers. Carbohydr Polym 87:1105–1111CrossRefGoogle Scholar
  29. 29.
    Jeong YI, Na HS, Oh JS, Choi KC, Song CE, Lee HC (2006) Adriamycin release from self-assembling nanospheres of poly(dl-lactide-co-glycolide)-grafted pullulan. Int J Pharm 322:154–160CrossRefGoogle Scholar
  30. 30.
    Jung SW, Jeong YI, Kim SH (2003) Characterization of hydrophobized pullulan with various hydrophobicities. Int J Pharm 254:109–121CrossRefGoogle Scholar
  31. 31.
    Park KH, Kang DM, Na K (2006) Physicochemical characterization and carcinoma cell interaction of selforganized nanogels prepared from polysaccharide/biotin conjugates for development of anticancer drug carrier. Int J Microbiol Biotechnol 16:1369–1376Google Scholar
  32. 32.
    Lu D, Wen X, Liang J, Gu Z, Zhang X, Fan Y (2009) A pH-sensitive nano drug delivery system derived from pullulan/doxorubicin conjugate. J Biomed Mater Res B Appl Biomater 89:177–183CrossRefGoogle Scholar
  33. 33.
    Lei H, Cao P, Miao G, Lin Z, Diao Z (2010) Expression and functional characterization of tumor-targeted fusion protein composed of NGR peptide and 15-kDa actin fragment. Appl Biochem Biotechnol 162:988–995CrossRefGoogle Scholar
  34. 34.
    Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F (2008) Aminopeptidase N (APN)/CD13 inhibitor, ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer 8:74CrossRefGoogle Scholar
  35. 35.
    Ryakhovsky VV, Khachiyan GA, Kosovova NF, Isamiddinova EF, Ivanov AS (2008) The first preparative solution phase synthesis of melanotan II. Beilstein. J Org Chem 4:39.  https://doi.org/10.3762/bjoc.4.39 Google Scholar
  36. 36.
    Leibler L, Orland H, Wheeler JC (1983) Theory of critical micelle concentration for solutions of block copolymers. J Chem Phys 79:3550–3557CrossRefGoogle Scholar
  37. 37.
    Wolszczak M, Miller J (2002) Characterization of non-ionic surfactant aggregates by fluorometric techniques. J Photochem Photobiol A Chem 147:45–54CrossRefGoogle Scholar
  38. 38.
    Fattahi A, Golozar MA, Varshosaz J, Sadeghi HM, Fathi M (2012) Preparation and characterization of micelles of oligomeric chitosan linked to all-trans retinoic acid. Carbohydr Polym 87:1176–1184CrossRefGoogle Scholar
  39. 39.
    Varshosaz J, Hassanzadeh F, Aliabadi HS, Banitalebi M, Rostami M, Nayebsadrian M (2014) Novel worm-like amphiphilic micelles of folate-targeted cyclodextrin/retinoic acid for delivery of doxorubicin in KG-1 cells. Colloid Polym Sci 292:2647–2662CrossRefGoogle Scholar
  40. 40.
    Varshosaz J, Hassanzadeh F, Sadeghi-Aliabadi H, Larian Z, Rostami M (2014) Synthesis of Pluronic® F127-poly(methyl vinyl ether-alt-maleic acid) copolymer and production of its micelles for doxorubicin delivery in breast cancer. Chem Eng J 240:133–146CrossRefGoogle Scholar
  41. 41.
    Costa P, Lobo JMS (2001) Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–133CrossRefGoogle Scholar
  42. 42.
    Triola G, Gerauer M, Görmer K, Brunsveld L, Waldmann H (2010) Solid-phase synthesis of lipidated Ras peptides employing the ellman sulfonamide linker. Chem Eur J 16:9585–9591CrossRefGoogle Scholar
  43. 43.
    Carpino LA, Ghassemi S, Ionescu D, Ismail M, Sadat-Aalaee D, Truran GA, Mansour E, Siwruk GA, Eynon JS, Morgan B (2003) Rapid, continuous solution-phase peptide synthesis: application to peptides of pharmaceutical interest. Org Proc Res Dev 7:28–37CrossRefGoogle Scholar
  44. 44.
    Hojo K, Ichikawa H, Onishi M, Fukumori Y, Kawasaki K (2011) Peptide synthesis ‘in water’ by a solution-phase method using water-dispersible nanoparticle Boc-amino acid. J Pept Sci 17:487–492CrossRefGoogle Scholar
  45. 45.
    Yang Y, Xie X, Yang Y, Zhang H, Mei X (2015) Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy. J Pharm Sci 104:1328–1339CrossRefGoogle Scholar
  46. 46.
    Lee J, Jeong D, Seo S, Na K (2013) Biodegradable nanogel based on all-trans retinoic acid/pullulan conjugate for anti-cancer drug delivery. J Pharm Investig 43:63–69CrossRefGoogle Scholar
  47. 47.
    Xu W, Ling P, Zhang T (2013) Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv 2013:1–15CrossRefGoogle Scholar
  48. 48.
    Nayebsadrian M, Varshosaz J, Hassanzadeh F, Sadeghi H, Banitalebi M, Rostami M (2012) Screening the most effective variables on physical properties of folate-targeted dextran/retinoic acid micelles by Taguchi design. J Nanomater 2012:133.  https://doi.org/10.1155/2012/860691 CrossRefGoogle Scholar
  49. 49.
    Bhardwaj SB, Shukla AJ, Collins CC (1995) Effect of varying drug loading on particle size distribution and drug release kinetics of verapamil hydrochloride microspheres prepared with cellulose esters. J Microencapsul 12:71–81CrossRefGoogle Scholar
  50. 50.
    Honary S, Zahir F (2013) Effect of zeta potential on the properties of nano-drug delivery systems—a review (part 1). Trop J Pharm Res 12:255–264Google Scholar
  51. 51.
    Hunter RJ (1981) Chapter 2: Charge and potential distribution at interfaces. In: Zeta potential in colloid science. Academic Press, Boca Raton. pp 11–58.  https://doi.org/10.1016/B978-0-12-361961-7.50006-7
  52. 52.
    Nagarajan R, Barry M, Ruckenstein E (1986) Unusual selectivity in solubilization by block copolymer micelles. Langmuir 2:210–215CrossRefGoogle Scholar
  53. 53.
    Xing L, Mattice WL (1997) Strong solubilization of small molecules by triblock-copolymer micelles in selective solvents. Macromolecules 30:1711–1717CrossRefGoogle Scholar
  54. 54.
    Kamba SA, Ismail M, Hussein-Al-Ali SH, Ibrahim TAT, Zakaria ZAB (2013) In vitro delivery and controlled release of doxorubicin for targeting osteosarcoma bone cancer. Molecules 18:10580–10598CrossRefGoogle Scholar
  55. 55.
    Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65:157–170CrossRefGoogle Scholar
  56. 56.
    Ito T, Sun L, Bevan MA, Crooks RM (2004) Comparison of nanoparticle size and electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, dynamic light scattering, transmission electron microscopy, and phase analysis light scattering. Langmuir 20:6940–6945CrossRefGoogle Scholar
  57. 57.
    Pabisch S, Feichtenschlager B, Kickelbick G, Peterlik H (2012) Effect of interparticle interactions on size determination of zirconia and silica based systems—a comparison of SAXS, DLS, BET, XRD and TEM. Chem Phys Lett 521:91–97CrossRefGoogle Scholar
  58. 58.
    Berridge MV, Herst PM, Tan AS (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11:127–152CrossRefGoogle Scholar
  59. 59.
    Lotan R, Kramer RH, Neumann G, Lotan D, Nicolson GL (1980) Retinoic acid-induced modifications in the growth and cell surface components of a human carcinoma (HeLa) cell line. Exp Cell Res 130:401–414CrossRefGoogle Scholar
  60. 60.
    Ye L, Song Q (2015) Promising potency of retinoic acid–poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment. Int J Clin Exp Med 8:10501–10507Google Scholar

Copyright information

© Iran Polymer and Petrochemical Institute 2018

Authors and Affiliations

  1. 1.Novel Drug Delivery Systems Research Centre and Department of Medicinal Chemistry, School of PharmacyIsfahan University of Medical SciencesIsfahanIran
  2. 2.Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical SciencesIsfahan University of Medical SciencesIsfahanIran
  3. 3.Novel Drug Delivery Systems Research Center and Department of Pharmaceutics, School of Pharmacy and Pharmaceutical SciencesIsfahan University of Medical SciencesIsfahanIran
  4. 4.Department of Pharmacognosy, School of Pharmacy and Pharmaceutical SciencesIsfahan University of Medical SciencesIsfahanIran
  5. 5.Applied Physiology Research Center, Cardiovascular Research InstituteIsfahan University of Medical SciencesIsfahanIran

Personalised recommendations